Core Viewpoint - Guichuang Tongqiao is seeking new growth points by acquiring a 49% stake in German medical device manufacturer Optimed for €18.375 million, with options for future full acquisition, aiming to expand its presence in Europe and globally [1][3]. Group 1: Acquisition Details - The acquisition of Optimed, established in 1996, focuses on minimally invasive vascular and urological intervention medical devices, with a sales network covering over 70 countries [1]. - The deal will allow Guichuang Tongqiao to leverage Optimed's established R&D, manufacturing, and commercialization platforms in Europe to enhance its international market presence [1][4]. Group 2: Financial Performance and Growth Strategy - Guichuang Tongqiao is projected to achieve its first profit in 2024, with a forecasted profit of 121 million yuan in the first half of 2025, driven by the implementation of high-value medical consumables procurement policies in China [3]. - In the first half of 2025, the company reported revenues of 482 million yuan, with international business contributing 15.7 million yuan, a 36.9% increase, primarily from Europe and Asia [3]. - The company aims to strengthen its global strategy, focusing on the vast potential of the overseas intervention consumables market, particularly in Europe and emerging markets, where price stability and long-term profit assurance exist [3]. Group 3: Challenges and Integration Plans - The company acknowledges the challenges faced in building brand and channel presence in overseas markets, which differ from the outbound strategies of domestic innovative pharmaceuticals [3]. - Post-acquisition, Guichuang Tongqiao plans to integrate commercial platforms with Optimed, including existing sales networks, academic promotion teams, and customer service systems, to accelerate clinical trials and commercialization of products in international markets [4].
补强欧洲销售渠道，归创通桥收购德国介入耗材厂商